ES2042751T3 - Nuevo procedimiento para la purificacion de viriones de la hepatitis a. - Google Patents

Nuevo procedimiento para la purificacion de viriones de la hepatitis a.

Info

Publication number
ES2042751T3
ES2042751T3 ES88307100T ES88307100T ES2042751T3 ES 2042751 T3 ES2042751 T3 ES 2042751T3 ES 88307100 T ES88307100 T ES 88307100T ES 88307100 T ES88307100 T ES 88307100T ES 2042751 T3 ES2042751 T3 ES 2042751T3
Authority
ES
Spain
Prior art keywords
hepatitis
purification
virions
new procedure
hav
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES88307100T
Other languages
English (en)
Spanish (es)
Inventor
John A Lewis
Emilio A Emini
Marcy E Armstrong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Application granted granted Critical
Publication of ES2042751T3 publication Critical patent/ES2042751T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/29—Antimony or bismuth compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32451—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Catalysts (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Physical Water Treatments (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Non-Flushing Toilets (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Bidet-Like Cleaning Device And Other Flush Toilet Accessories (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ES88307100T 1987-08-06 1988-08-01 Nuevo procedimiento para la purificacion de viriones de la hepatitis a. Expired - Lifetime ES2042751T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8272087A 1987-08-06 1987-08-06

Publications (1)

Publication Number Publication Date
ES2042751T3 true ES2042751T3 (es) 1993-12-16

Family

ID=22173006

Family Applications (1)

Application Number Title Priority Date Filing Date
ES88307100T Expired - Lifetime ES2042751T3 (es) 1987-08-06 1988-08-01 Nuevo procedimiento para la purificacion de viriones de la hepatitis a.

Country Status (16)

Country Link
US (1) US5521082A (enExample)
EP (1) EP0302692B1 (enExample)
JP (1) JPH0648980B2 (enExample)
KR (1) KR970001711B1 (enExample)
AT (1) ATE84067T1 (enExample)
AU (1) AU612168B2 (enExample)
CY (1) CY1773A (enExample)
DE (1) DE3877082T2 (enExample)
DK (1) DK173215B1 (enExample)
ES (1) ES2042751T3 (enExample)
GR (1) GR3007158T3 (enExample)
IE (1) IE61294B1 (enExample)
IL (1) IL87257A0 (enExample)
NZ (1) NZ225583A (enExample)
PT (1) PT88178B (enExample)
ZA (1) ZA885726B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8913665D0 (en) * 1989-06-14 1989-08-02 Univ Birmingham Method of preparing vaccines against rna viruses
CA2047041A1 (en) * 1990-07-18 1992-01-19 John A. Lewis Process for purification of hepatitis-a virus capsids
JPH0834362B2 (ja) * 1991-03-08 1996-03-29 ローム株式会社 電気部品取り外し機
GB9111230D0 (en) * 1991-05-24 1991-07-17 Wellcome Found Virus production
US5506129A (en) * 1991-05-24 1996-04-09 Evans Medical Limited Virus production
IT1248075B (it) * 1991-06-18 1995-01-05 Sclavo Spa Processo per la purificazione del virus dell'epatite a (hav), virus cosi` purificato e composizioni vaccinali che lo contengono.
FR2686084B1 (fr) * 1992-01-10 1995-12-22 Bioprojet Soc Civ Nouveaux derives de l'imidazole, leur preparation et leurs applications therapeutiques.
USRE37303E1 (en) * 1992-01-10 2001-07-31 Institut National Del La Sante Et De La Recherche Medicale Imidazole compounds and their therapeutic applications
DZ1706A1 (fr) 1992-08-07 2002-02-17 Merck & Co Inc Vaccin contre le virus de l'hepatite a.
FR2696748B1 (fr) 1992-10-14 1994-12-30 Pasteur Merieux Serums Vacc Procédé de préparation d'antigènes et de vaccins de l'hépatite A (HAV).
HRP950097A2 (en) 1994-03-08 1997-06-30 Merck & Co Inc Hepatitis a virus culture process
PT751988E (pt) * 1994-03-22 2000-05-31 Immune Response Corp Inc Producao e isolamento altamente eficientes de particulas virais
WO1997008298A1 (en) 1995-08-30 1997-03-06 Genzyme Corporation Chromatographic purification of adenovirus and aav
US6261823B1 (en) 1996-12-13 2001-07-17 Schering Corporation Methods for purifying viruses
US20080261289A1 (en) * 1996-12-13 2008-10-23 Schering-Plough Corporation Compositions comprising viruses and methods for concentrating virus preparations
US6544769B1 (en) * 1996-12-13 2003-04-08 Schering Corporation Compostions comprising viruses and methods for concentrating virus preparations
US6783939B2 (en) * 2000-07-07 2004-08-31 Alphavax, Inc. Alphavirus vectors and virosomes with modified HIV genes for use in vaccines
KR100762477B1 (ko) * 2001-05-31 2007-10-02 주식회사 포스코 고로의 출선구 개공장치
EP1432791B2 (en) * 2001-09-06 2013-10-23 Alphavax, Inc. Alphavirus replicon vector systems
US20050272029A1 (en) * 2002-08-16 2005-12-08 Bertrand Saunier Hepatitis c viral-like particle purification
CA2509973C (en) * 2002-12-13 2013-02-26 Alphavax, Inc. Multi-antigenic alphavirus replicon particles and methods
EP1608762B1 (en) * 2003-03-20 2014-01-08 Alphavax, Inc. Improved alphavirus replicons and helper constructs
ATE432285T1 (de) * 2003-07-11 2009-06-15 Alphavax Inc Cytomegalovirusimpfstoffe, die auf dem alphavirus basieren
NZ582495A (en) 2007-06-21 2012-05-25 Alphavax Inc Promoterless cassettes for expression of alphavirus structural proteins
BR112012026095A2 (pt) 2010-04-14 2015-09-15 Emd Millipore Corp métodos de produção de estoques de vírus de alta pureza e altos títulos e métodos de uso dos mesmos.
MY192159A (en) * 2015-10-15 2022-08-03 Biocon Ltd Method for detecting neutralizing antibodies against recombinant human insulin in human serum
EP3695849A1 (en) 2019-02-13 2020-08-19 Mediagnost Gesellschaft für Forschung und Herstellung von Diagnostika GmbH Method for extracting hepatitis a virus (hav) antigen from cell culture

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7216091A (enExample) * 1971-12-03 1973-06-05
US3919044A (en) * 1973-03-28 1975-11-11 Armour Pharma Processes for concentrating and purifying viruses and viral antigens
US3994870A (en) * 1974-01-31 1976-11-30 The Community Blood Council Of Greater New York, Inc. Purification of hepatitis B surface antigen
FR2398504A1 (fr) * 1977-07-29 1979-02-23 Tours Inst Virologie Culture de virus de l'hepatite a, in vitro. application a la production d'un antigene reactif, d'immunserums specifiques et de vaccins contre l'hepatite a
US4164566A (en) * 1978-08-17 1979-08-14 Merck & Co., Inc. Hepatitis a virus cell culture in vitro
US4894228A (en) * 1982-04-07 1990-01-16 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against hepatitis A virus
US4614793A (en) * 1983-10-14 1986-09-30 Merck & Co., Inc. Hepatitis A--subunit antigen
US4683294A (en) * 1985-04-03 1987-07-28 Smith Kline Rit, S.A. Process for the extraction and purification of proteins from culture media producing them
IT1248075B (it) * 1991-06-18 1995-01-05 Sclavo Spa Processo per la purificazione del virus dell'epatite a (hav), virus cosi` purificato e composizioni vaccinali che lo contengono.

Also Published As

Publication number Publication date
IE882407L (en) 1989-02-06
DK437988A (da) 1989-04-04
DE3877082D1 (de) 1993-02-11
PT88178A (pt) 1989-06-30
IE61294B1 (en) 1994-10-19
US5521082A (en) 1996-05-28
CY1773A (en) 1995-10-20
JPS6451080A (en) 1989-02-27
DK173215B1 (da) 2000-04-03
ATE84067T1 (de) 1993-01-15
PT88178B (pt) 1995-03-01
KR890003407A (ko) 1989-04-14
EP0302692A3 (en) 1990-02-14
EP0302692A2 (en) 1989-02-08
KR970001711B1 (ko) 1997-02-14
NZ225583A (en) 1991-07-26
DE3877082T2 (de) 1993-06-03
GR3007158T3 (enExample) 1993-07-30
IL87257A0 (en) 1988-12-30
AU612168B2 (en) 1991-07-04
EP0302692B1 (en) 1992-12-30
DK437988D0 (da) 1988-08-05
JPH0648980B2 (ja) 1994-06-29
ZA885726B (en) 1989-04-26
AU2051888A (en) 1989-03-23

Similar Documents

Publication Publication Date Title
ES2042751T3 (es) Nuevo procedimiento para la purificacion de viriones de la hepatitis a.
DK0541507T3 (da) Thrombin samt fremgangsmåde til dets fremstilling
ATE119042T1 (de) Verwendung eines viralen glykoprotein-impstoffes für intranasale immunisierung gegen eine virusinfektion.
DK0435443T3 (da) Anvendelse af en 15-ketoprostaglandinforbindelse til forbedring af den encephaliske funktion
SE7600284L (sv) Terapeutisk insulinberedning.
ES487046A1 (es) Procedimiento de preparacion de proteoglicanos membranarios bacterianos purificados
ES2058283T3 (es) Vacuna contra coronavirus canino.
ES2130189T3 (es) Vacunas de virus sincitial respiratorio (rsv) mutante que contienen dicho virus y procedimientos de uso.
ES292573Y (es) Autoclave de esterilizacion por medio de un gas o de una mezcla de gas-vapor.
ATE121779T1 (de) Nichtzurückschlagende rns-viren.
DK495786D0 (da) Fremgangsmaade til fremstilling af halogen-magnesium-alanat og alanatets anvendelse
ES2000435T3 (es) Procedimiento de purificacion de antigenos proteinicos de bacterias que pertenecen al genero bordetella, en vista a la obtencion de una vacuna acelular.
ES2063156T3 (es) Nuevos derivados lisogangliosidos.
ES2033273T3 (es) Procedimiento para la obtencion de terpolimeros.
ES446637A1 (es) Procedimiento para la preparacion de vacunas acelulares.
ES2059323T3 (es) Procedimiento para la produccion de una preparacion de inmunoglobulina pasteurizada.
KR790000143B1 (en) Method for preparation of cyanophenyl carbonate
DE68925356D1 (de) Nicht-zurückmutierende RNA-Viren
ES2045146T3 (es) Avermectinas etiladas.
ES476405A1 (es) Un metodo para la preparacion de 2-metiltio-6-fluoro-9-(1- metil-4-piperilideno)-tioxanteno
ES2040873T3 (es) Un metodo de purificacion de una solucion acuosa de m-aminofenol.
ES258136Y (es) Conjunto para conectar un paciente,por medio de un tarro,conuna fuente de vacio
GT198065142A (es) Purinas sustituidas.
SU1114024A1 (ru) N-(n-фенол)-дихлормалеинимид, проявляющий активность в отношении сульфатвосстанавливающих бактерий
SU1614204A1 (ru) Дезинфицирующее средство

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 302692

Country of ref document: ES